‘Unstoppable’ seven-year-old fundraises for Sheffield Children’s
Seven-year-old Harmony from Sheffield is supporting The Children’s Hospital Charity by taking part in Theo’s Pyjama Day in thanks for the lifelong care she receives at Sheffield Children’s.
Electromed targets double-digit growth in FY2025 with SmartVest expansion and CRM upgrades
Strategic investments included expanding the salesforce to 54 representatives, with a goal of reaching 57 by the end of Q3 FY2025. A new CRM system was initiated to enhance sales team productivity and ...
Stifel raises Insmed stock target to $97, maintains Buy rating
Stifel analysts maintained their Buy rating on Insmed shares (NASDAQ:INSM) and increased the price target from $88.00 to $97.00. According to InvestingPro data, the stock has delivered an impressive ...
Healio2d
FDA grants brensocatib priority review for bronchiectasis
The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...
Insmed: Priority Review For Brensocatib Cements (Limited) Upside Opportunity
Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...
Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review
The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.
pharmaphorum5d
FDA starts review of first bronchiectasis drug candidate
The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...
The Pharma Letter5d
FDA Priority Review for Insmed's brensocatib for bronchiectasis
The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for brensocatib for patients with ...
FDA grants priority review for potential bronchiectasis treatment
BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $14.57 ...
Insmed Gets Speedy FDA Review of Brensocatib for Bronchiectasis
The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...
Insmed: FDA accepts NDA for brensocatib
Insmed (INSM) announced that the U.S. FDA has accepted the company’s New Drug Application for brensocatib for patients with non-cystic fibrosis ...